FDA Approves Daridorexant for Treatment of Insomnia

Home
Forums
FDA Updates
FDA Approves Daridorexant for Treatment of Insomnia

Tagged: Approvals, FDA Updates

This topic has 0 replies, 1 voice, and was last updated 2 years, 10 months ago by TDP.

Viewing 0 reply threads

Author

Posts
- January 10, 2022 at 1:59 am #48668
  
  TDP
  Keymaster
  
  Media Release
  January 10, 2022
  
  Idorsia receives US FDA approval of QUVIVIQ (daridorexant)
  25 and 50 mg for the treatment of adults with insomnia
  
  Use: Labeled Indications
  
  Insomnia, sleep onset or sleep maintenance: Treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, in adults.
  
  Contraindications
  
  Narcolepsy.
  
  Products
  
  Quviviq: FDA approved January 2022; anticipated availability in May 2022.
  
  FDA Approval Date
  
  January 10, 2022
Author

Posts

Viewing 0 reply threads

You must be logged in to reply to this topic.